📚 How Stock DNA Is Calculated
Every Stock DNA score comes from a fixed, published formula — not a subjective opinion. This page explains, category by category, exactly what inputs feed each 0–100 score, and how those 10 scores combine into the single composite DNA score you see on every stock's page.
The Composite Score
Each of the 10 categories below is scored independently, on its own 0–100 scale, from the stock's own fundamentals, price/technical data, and third-party inputs (news headlines, analyst estimates). The composite score is a weighted average of every category that has enough data to be scored — if a category is unavailable for a given stock, it's dropped and the remaining weights scale up proportionally, so the composite always lands on a 0–100 scale. Risk is inverted (100 minus its raw score) before being folded in, since a high Risk score means high risk, not a strong DNA.
The composite score, rounded to the nearest whole number, maps to one of five tiers:
The 10 Genome Categories
Blends profitability margins (gross/operating/net), returns on capital (ROE, ROIC), balance-sheet health (current ratio, net debt/EBITDA, free-cash-flow conversion), Piotroski F-Score, and the recent quarter-over-quarter revenue/margin trend.
Based on price position relative to the 50- and 200-day moving averages, whether a Golden/Death Cross has occurred, trend strength (ADX), and a Supertrend signal.
Based on 20-day rate of change, the MACD histogram, Stochastic RSI, and 14-day RSI.
Based on where the current price sits within its own 2-year high/low range.
Based on P/E, P/B, PEG, dividend yield, and free-cash-flow yield, benchmarked against a typical "fair" P/E range for the stock's sector.
Based on sentiment analysis (positive vs. negative split) across recent news headlines about the stock.
Based on % of shares held by institutions and insiders, the number of institutions reporting a position, and whether recent institutional activity has been increasing or decreasing.
Based on On-Balance Volume trend, distance from VWAP, relative volume, and the most recent recognized candlestick pattern.
Based on beta, annualized volatility, maximum 2-year drawdown, balance-sheet red flags, and short interest. A higher score here means more risk, so this category is inverted (100 minus the score) before it's folded into the composite below.
Based on third-party analyst price targets and consensus rating, forward earnings/revenue growth estimates, recent EPS estimate revisions, and the stock's sector cycle phase. Dampened toward neutral when fewer than 3 analysts cover the stock.
Not investment advice. StockDNA is not a registered Investment Adviser or Research Analyst. These are descriptive, historical/current-data calculations, not predictions, ratings, or buy/sell recommendations — please do your own research and consult a licensed financial advisor before making any investment decision. See a live example on any stock's DNA page.